Middle East Anti-Depressants Drugs Market Report 2022 to 2030

Middle East Anti-Depressants Drugs Market Analysis

$ 3999

The Middle East Anti-Depressants drugs market size was valued at $3.12 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 5.9% from 2022 to 2030 and will reach $4.64 Bn in 2030. The market is segmented by drug class, indication, route of administration, end-user, and distribution channel. The Middle East Anti-Depressants drug market will grow because Depression is a common mental health disorder in the Middle East, affecting a significant portion of the population. The key market players are GlaxoSmithKline plc (GBR), AstraZeneca (GBR), Mallinckrodt (GBR), Novartis AG, and others.

ID: IN10MEPH051 CATEGORY: Pharmaceuticals GEOGRAPHY: Middle East AUTHOR: Chandani Patel

Buy Now

Middle East Anti-Depressants Drugs Market Executive Summary

The Middle East Anti-Depressants drugs market size was valued at $3.12 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 5.9% from 2022 to 2030 and will reach $4.64 Bn in 2030. One out of every 7 people living in Middle - East countries is suffering from diabetes. Nevertheless, the prevalence of diabetes varied from about 3% in Israel to more than 21.9% in Kuwait. Importantly, it has increased considerably during the last two decades from about 9% to nearly 19% in the region. According to the International Diabetes Federation (IDF), the Middle East and North Africa region (MENA) has the highest prevalence of diabetes among adults aged 20-79 years globally, with an estimated 51 million people living with the condition in 2021. The IDF also estimates that the prevalence of diabetes in the region will increase by 69% between 2021 and 2045.

Within the Middle East, the countries with the highest prevalence of diabetes include Kuwait, Qatar, Saudi Arabia, and the United Arab Emirates. In these countries, the prevalence of diabetes ranges from 16% to 20% among adults aged 20-79 years. Factors contributing to the high prevalence of diabetes in the Middle East include rapid urbanization, changes in lifestyle, and increased rates of obesity and physical inactivity. There is also a high prevalence of risk factors such as tobacco use and unhealthy diets, as well as genetic and environmental factors that may increase the risk of developing diabetes. The high prevalence of diabetes in the Middle East could have an impact on the anti-depressant drugs market, although the nature and extent of this impact would depend on various factors. One potential impact could be an increased demand for anti-depressant drugs among people with diabetes who also experience depression or other mental health issues. Studies have found that people with diabetes are at higher risk of depression than the general population, with rates estimated to be as high as 30%.

This increased demand could lead to a rise in sales of anti-depressant drugs in the Middle East, particularly in countries with high prevalence rates of diabetes. However, the extent of this impact may be limited by factors such as the availability and affordability of these drugs, as well as cultural attitudes towards mental health treatment. It's also worth noting that the link between diabetes and depression is complex, and addressing the root causes of both conditions may require a multifaceted approach that includes lifestyle interventions, psychological support, and medical treatment for both conditions. Overall, while the high prevalence of diabetes in the Middle East could potentially impact the anti-depressant drugs market, the relationship between these two factors is likely to be complex and multifactorial.

middle east anti-depressants drugs market

Market Dynamics

Market Growth Drivers

Growing incidence of depression: Depression is a common mental health disorder in the Middle East, affecting a significant portion of the population. The increasing incidence of depression is driving the demand for antidepressant drugs.
Increasing awareness of mental health: There is a growing awareness of mental health disorders in the Middle East, including depression. This is leading to increased diagnosis and treatment of depression, which is driving the demand for antidepressant drugs.
Favorable government initiatives: Governments in the Middle East are increasingly focusing on mental health as a public health priority. They are implementing various initiatives to improve mental health services, including the availability of antidepressant drugs.
Increasing healthcare expenditure: Healthcare expenditure is increasing in the Middle East, leading to improved access to healthcare services, including mental health services.

Market Restraints

Stigma associated with mental health disorders: Mental health disorders are still stigmatized in the Middle East, which may discourage people from seeking treatment for depression.
Limited availability of healthcare professionals: There is a shortage of healthcare professionals in the Middle East, particularly in the mental health sector. This can limit access to mental health services, including antidepressant drugs.
High cost of antidepressant drugs: Antidepressant drugs can be expensive, which may limit access for some individuals in the Middle East.
Lack of regulatory framework: The Middle East lacks a uniform regulatory framework for the approval and distribution of drugs, including antidepressant drugs. This can lead to delays in drug approvals and distribution, which can limit access to antidepressant drugs.

Competitive Landscape

Key Players

GlaxoSmithKline plc
AstraZeneca
Novartis AG
Endo Pharmaceuticals plc
Johnson & Johnson
Apotex Inc.
Bausch Health Companies Inc.
Lundbeck
Purdue Pharma
Takeda Pharmaceutical Company Limited
Merck & Co., Inc.
AbbVie Inc.
Mylan N.V.
Novartis AG

Healthcare Policies and Regulatory Landscape

United Arab Emirates (UAE): The UAE Ministry of Health and Prevention regulates the registration and approval of drugs, including antidepressants. To be approved for sale, drugs must go through a rigorous process that includes clinical trials and review by the ministry. In the UAE, many antidepressants are available for purchase over the counter without a prescription. However, in order to obtain reimbursement for prescription antidepressants, patients must have health insurance that covers mental health conditions.

Saudi Arabia: The Saudi Food and Drug Authority regulates the registration and approval of drugs, including antidepressants. To be approved for sale, drugs must go through a rigorous process that includes clinical trials and review by the authority. In Saudi Arabia, reimbursement for prescription antidepressants is available through the government's healthcare program for Saudi nationals and residents.

Qatar: The Qatar Ministry of Public Health regulates the registration and approval of drugs, including antidepressants. To be approved for sale, drugs must go through a rigorous process that includes clinical trials and review by the ministry. In Qatar, reimbursement for prescription antidepressants is available through the government's healthcare program for Qatari nationals and residents.

Egypt: The Egyptian Drug Authority regulates the registration and approval of drugs, including antidepressants. To be approved for sale, drugs must go through a rigorous process that includes clinical trials and review by the authority. In Egypt, reimbursement for prescription antidepressants is available through the government's healthcare program for Egyptian citizens.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Anti-Depressants Drugs Market Segmentation

Drug Class

The market is divided into monoamine oxidase inhibitors, atypical antidepressants, tricyclic, serotonin, and norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors, and others based on pharmacological class. In 2021, the selective serotonin reuptake inhibitors (SSRIs) market segment held the biggest market share. The strength of the pipeline of top players to assess new potential candidates in this drug class, combined with the clinical advantage of SSRIs over conventional medications in the management and treatment of depression, is anticipated to accelerate the segment's growth.

Tricyclic Antidepressants (TCAs) - Amitriptyline (Elavil), Amoxapine (Asendin), Desipramine (Norpramin), Doxepin (Silenor), Imipramine (Tofranil), Nortriptyline (Pamelor), Protriptyline (Vivactil), Trimipramine (Surmontil)
Selective Serotonin Reuptake Inhibitors (SSRIs) - Citalopram (Cipramil), Dapoxetine (Priligy), Escitalopram (Cipralex), Fluoxetine (Prozac or Oxactin), Fluvoxamine (Faverin), Paroxetine (Seroxat), Sertraline (Lustral), Vortioxetine (Brintellix)
Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) - Desvenlafaxine (Pristiq), Duloxetine (Cymbalta), Levomilnacipran (Fetzima), Venlafaxine (Effexor XR)
Monoamine Oxidase Inhibitors (MAOIs) - Socarboxazid (Marplan), Phenelzine (Nardil), Selegiline (Emsam), Tranylcypromine (Parnate)
Serotonin Antagonist and Reuptake Inhibitors (SARI) - Etoperidone (Axiomin, Etonin), Lorpiprazole (Normarex), Mepiprazole (Psigodal), Nefazodone (Serzone, Nefadar), Trazodone (Desyrel)
Others

Indication

By Indication, the major depressive disorder segment was the major contributor in 2021 and is expected to maintain its lead during the forecast period, owing to an increase in the prevalence of major depressive disorder and initiatives taken by governments and private organizations about the development of drugs. However, the obsessive-compulsive disorder segment is expected to witness considerable growth during the forecast period, owing to an increase in the prevalence of mental disorders and an increase in the number of approval for anxiety drugs.

Major Depressive Disorder
Anxiety Disorders
Attention Deficit Hyperactivity Disorder
Others

Route of Administration

Based on the route of administration the market is segmented into:

Oral
Injectable
Others

End-Users

Based on end users the market is segmented into:

Hospitals
Homecare
Speciality Centres
Others

Distribution Channel

Hospital pharmacies, retail pharmacies, and online pharmacies are the three types of pharmacies that make up the market based on the distribution channel. In 2019, the hospital pharmacies segment dominated the world market. Nonetheless, the expansion of the retail pharmacy market might be attributed to patients' increasing demand for these establishments. Due to the growing prevalence of online pharmacies in emerging countries, the segment of online pharmacies is estimated to see a profitable CAGR over the forecast timeframe.

Hospital Pharmacy
Online Pharmacy
Retail Pharmacy

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.